To further decipher the role of chemokine induction and immune activation in the overall olaparib therapy effect, we inoculated immunocompetent C57BL/6 mice with ID8-Trp53(−/−)Brca2(−/−)* tumour cells susceptible to olaparib-induced cytotoxicity but not to chemokine induction. This evidence concerns the gene BRCA2 and neoplasm.